[Primary and secondary prevention of atherosclerotic disease by lipid-lowering therapies].
Epidemiological studies have shown close relationships between serum cholesterol levels and incidences of coronary heart disease (CHD). Primary and secondary prevention trials with cholesterol lowering have shown definite corresponding reductions in CHD. 4S in secondary prevention and WOS in primary prevention of hypercholesterolemic patients, CARE and LIPID in secondary prevention and CAPS in primary prevention in patients with average serum cholesterol levels have shown reduction of CHD. LDL-apheresis is more effective than medical treatment in heterozygous FH patients with CHD. Gemfibrozil is effective in secondary prevention of low HDL-cholesterolemic patients. Thus, for primary and secondary prevention of CHD the lower serum cholesterol level is the better.